(Total Views: 299)
Posted On: 09/06/2018 10:45:20 AM
Post# of 72446
Kelt and Pete:
I suspect you know this, but this was a footnote on the purchase agreement that was part of the last 8K on June 28th....Hence, there is no question that B-OM is the indication for the proposed licensing agreement and the milestone related to the deal. I agree with Pete....they know there is significant potential with B and they can pursue those other indications once they have a licensing agreement in place for B-OM.
(c) “BD Agreement” means a significant licensing arrangement with a pharmaceutical company that will include an initial (“up-front”) payment to the Company in an amount in the double-digits millions of dollars and will arrange for such pharmaceutical company to undertake the continuing development of the Company’s Brilacidin compound in the indication of Oral Mucositis, including the conducting and funding of clinical trials aiming towards the filing of an NDA.
I suspect you know this, but this was a footnote on the purchase agreement that was part of the last 8K on June 28th....Hence, there is no question that B-OM is the indication for the proposed licensing agreement and the milestone related to the deal. I agree with Pete....they know there is significant potential with B and they can pursue those other indications once they have a licensing agreement in place for B-OM.
(c) “BD Agreement” means a significant licensing arrangement with a pharmaceutical company that will include an initial (“up-front”) payment to the Company in an amount in the double-digits millions of dollars and will arrange for such pharmaceutical company to undertake the continuing development of the Company’s Brilacidin compound in the indication of Oral Mucositis, including the conducting and funding of clinical trials aiming towards the filing of an NDA.
(6)
(0)
